Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Operating Expenses (2016 - 2025)

Ligand Pharmaceuticals' Operating Expenses history spans 16 years, with the latest figure at $45.8 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 12.63% year-over-year to $45.8 million; the TTM value through Dec 2025 reached $227.1 million, up 19.68%, while the annual FY2025 figure was $227.1 million, 19.68% up from the prior year.
  • Operating Expenses for Q4 2025 was $45.8 million at Ligand Pharmaceuticals, down from $60.5 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $81.5 million in Q1 2025 and bottomed at -$806000.0 in Q4 2021.
  • The 5-year median for Operating Expenses is $35.7 million (2021), against an average of $38.6 million.
  • The largest annual shift saw Operating Expenses tumbled 101.95% in 2021 before it surged 1944.79% in 2022.
  • A 5-year view of Operating Expenses shows it stood at -$806000.0 in 2021, then soared by 1944.79% to $14.9 million in 2022, then soared by 111.57% to $31.5 million in 2023, then surged by 66.72% to $52.4 million in 2024, then decreased by 12.63% to $45.8 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Operating Expenses are $45.8 million (Q4 2025), $60.5 million (Q3 2025), and $39.2 million (Q2 2025).